Recurrent and Metastatic HNSCC: New Insights and Real-World Evidence for Improved Patient Outcomes

STATEMENT OF NEED

Head and neck cancers represent a heterogeneous group of tumors that originate in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx, and larynx. An estimated 66,470 new cases are diagnosed in the United States annually, and 15,050 people die of the disease (Siegel et al, 2022). Approximately 90% of cases are classified as head and neck squamous cell carcinoma (HNSCC). Treatment of HNSCC is complicated by numerous factors, including differing therapeutic strategies based on tumor location and stage, human papillomavirus (HPV) status, the need to preserve surrounding organs and tissues, and impacts on quality of life (NCCN, 2023). Remaining up to date on emerging treatment options and management strategies for HNSCC is vital. This activity led by Assuntina Sacco, MD, Associate Professor of Medicine at Moores Cancer Center of UC San Diego Health, will provide new insights and real-world guidance for improved outcomes in recurrent and metastatic HNSCC.

TARGET AUDIENCE

Medical oncologists, surgical oncologists, radiation oncologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with head and neck squamous cell carcinoma (HNSCC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:
Distinguish histopathological, molecular, and clinical biomarkers that can inform prognosis and management of HNSCC
Incorporate emerging efficacy and safety data on novel immune checkpoint inhibitors into personalized care plans for patients with advanced recurrent/metastatic HNSCC
Apply strategies to prevent and mitigate immune-mediated adverse events
Evaluate supportive care measures that can help optimize survivorship care in patients who have received treatment for advanced recurrent/metastatic HNSCC